Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Genitourinary 1

Conditions

Neoplasm Metastasis 4Neoplasms 3Melanoma 3Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Select Advanced Solid Tumors 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pain 1Neuroectodermal Tumors 1Nervous System Diseases 1Neoplasms, Neuroepithelial 1Neoplasms, Nerve Tissue 1Lymphoma 1Liver Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Insulin-Like Growth Factor I, Resistance To 1Humoral Hypercalcemia Of Malignancy 1Gliosarcoma 1Glioma 1Glioblastoma 1Disease 1Dendritic Cell Sarcoma, Interdigitating 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1Brain Neoplasms 1

Interventions

pembrolizumab 166Nivolumab 111Ipilimumab 93Dacarbazine 44trametinib 36dabrafenib 34Vemurafenib 33binimetinib 23atezolizumab 23Temozolomide 21cemiplimab 18Paclitaxel 18encorafenib 17spartalizumab 16cobimetinib 15Carboplatin 14talimogene laherparepvec 13Cisplatin 13Cyclophosphamide 12lenvatinib 10Pemetrexed 10Gemcitabine 10Docetaxel 10durvalumab 9Drug Therapy 9Bevacizumab 9tremelimumab 8Injections 8Albumin-Bound Paclitaxel 8130-nm albumin-bound paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Melanoma × Antibodies, Monoclonal × Clear all
NCT01335009 2021-09-01

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

Eisai Inc.

Phase 2 Completed
76 enrolled 13 charts
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00356460 2014-03-19

Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma

Sanofi

Phase 1 Completed
29 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT00094653 2011-07-11

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Bristol-Myers Squibb

Phase 3 Completed
1,783 enrolled 29 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡